PE20190124A1 - Linfocitos t transfectados y receptores de linfocito t para el uso en la inmunoterapia contra el cancer - Google Patents
Linfocitos t transfectados y receptores de linfocito t para el uso en la inmunoterapia contra el cancerInfo
- Publication number
- PE20190124A1 PE20190124A1 PE2018001777A PE2018001777A PE20190124A1 PE 20190124 A1 PE20190124 A1 PE 20190124A1 PE 2018001777 A PE2018001777 A PE 2018001777A PE 2018001777 A PE2018001777 A PE 2018001777A PE 20190124 A1 PE20190124 A1 PE 20190124A1
- Authority
- PE
- Peru
- Prior art keywords
- present description
- lymphocytes
- peptides
- methods
- molecules
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K40/4269—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G01N33/575—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/47—Brain; Nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente descripcion se refiere a receptores de linfocito T (TCR) que se unen a antigenos asociados a tumor (TAA) y que permiten reconocer especificamente celulas cancerosas, a linfocitos T que expresan los mismos, a metodos para producir los mismos, y a metodos para tratar canceres con los mismos. En particular, la presente descripcion se refiere a varios TCR y a sus variantes que se unen a moleculas de HLA de clase I o II unidas con un peptido, como el IGF2BP3-001 dotado de la secuencia de aminoacidos KIQEILTQV (SEQ ID N: 1). La presente descripcion se refiere, ademas, a peptidos, proteinas, acidos nucleicos y celulas destinados a la utilizacion en metodos inmunoterapeuticos. En particular, la presente descripcion se refiere a la inmunoterapia contra el cancer. La presente descripcion se refiere, ademas, a epitopos peptidicos para linfocitos T que estan asociados a tumores, solos o en combinacion con otros peptidos asociados a tumores que, por ejemplo, pueden servir como principios activos farmaceuticos en composiciones vacunales destinadas a estimular respuestas inmunitarias antitumorales, o a estimular ex vivo linfocitos T que despues seran transferidos a los pacientes. Los peptidos unidos a moleculas del complejo mayor de histocompatibilidad (MHC), o los peptidos como tales, tambien pueden ser dianas de anticuerpos, de receptores de linfocitos T solubles, y de otras moleculas de union
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662308970P | 2016-03-16 | 2016-03-16 | |
| GBGB1604494.3A GB201604494D0 (en) | 2016-03-16 | 2016-03-16 | Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20190124A1 true PE20190124A1 (es) | 2019-01-17 |
Family
ID=55952419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2018001777A PE20190124A1 (es) | 2016-03-16 | 2017-03-16 | Linfocitos t transfectados y receptores de linfocito t para el uso en la inmunoterapia contra el cancer |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10537624B2 (es) |
| EP (1) | EP3430037B1 (es) |
| JP (1) | JP6929867B2 (es) |
| KR (1) | KR102266721B1 (es) |
| CN (1) | CN108884143A (es) |
| AU (1) | AU2017235069B2 (es) |
| BR (1) | BR112018067989A2 (es) |
| CA (1) | CA3017419A1 (es) |
| CR (1) | CR20180490A (es) |
| EA (1) | EA201891759A1 (es) |
| GB (1) | GB201604494D0 (es) |
| MA (2) | MA45309B1 (es) |
| MX (1) | MX2018011223A (es) |
| PE (1) | PE20190124A1 (es) |
| SG (1) | SG11201807590SA (es) |
| TW (1) | TWI788284B (es) |
| UA (1) | UA124532C2 (es) |
| WO (1) | WO2017158116A1 (es) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021173560A1 (en) | 2020-02-24 | 2021-09-02 | Immatics US, Inc. | Methods for expanding t cells for the treatment of cancer and related malignancies |
| MD3430037T2 (ro) * | 2016-03-16 | 2023-01-31 | Immatics Biotechnologies Gmbh | Celule T transfectate și receptori de celule T pentru utilizare în imunoterapie împotriva cancerelor |
| GB201604490D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides combination of peptides for use in immunotherapy against cancers |
| EP3578650A4 (en) * | 2017-02-06 | 2021-03-24 | National Cancer Center Japan | Novel t-cell receptor |
| CA3080546A1 (en) | 2017-10-03 | 2019-04-11 | Juno Therapeutics, Inc. | Hpv-specific binding molecules |
| JP2021513347A (ja) | 2018-02-11 | 2021-05-27 | メモリアル スローン ケタリング キャンサー センター | 非ｈｌａ制限ｔ細胞受容体およびその使用 |
| AU2019218397A1 (en) * | 2018-02-12 | 2020-10-01 | Fred Hutchinson Cancer Center | Cyclin A1 specific T cell receptors and uses thereof |
| EP3765491B1 (en) * | 2018-03-14 | 2024-04-03 | Medigene Immunotherapies GmbH | Inducible t cell receptors and uses thereof |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| BR112020019313A2 (pt) * | 2018-04-05 | 2021-01-05 | Juno Therapeutics Inc | Receptores de células t e células modificadas que expressam os mesmos |
| CN110938136B (zh) | 2018-09-21 | 2022-09-09 | 香雪生命科学技术（广东）有限公司 | 一种识别afp抗原的高亲和力t细胞受体 |
| US12179037B2 (en) | 2018-12-11 | 2024-12-31 | Board Of Regents, The University Of Texas System | Radiotherapies and uses thereof |
| ES2929585T3 (es) * | 2018-12-20 | 2022-11-30 | Ava Lifescience Gmbh | Procedimiento para la selección de moléculas de fijación biológicas |
| WO2020191172A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| DE102019108125B4 (de) | 2019-03-28 | 2022-02-03 | Immatics US, Inc. | Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung |
| TWI872076B (zh) | 2019-05-27 | 2025-02-11 | 美商英麥提克斯股份有限公司 | 病毒載體及其在授受性細胞療法之應用 |
| CN114245745A (zh) * | 2019-06-20 | 2022-03-25 | 纪念斯隆-凯特琳癌症中心 | 靶向pik3ca突变的t细胞受体及其用途 |
| CN110357953B (zh) * | 2019-07-17 | 2022-05-03 | 深圳市因诺转化医学研究院 | 识别人巨细胞病毒pp65抗原的TCR |
| WO2021022044A1 (en) * | 2019-07-31 | 2021-02-04 | Forty Seven, Inc. | Depletion regimes for engineered t-cell or nk-cell therapy |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| EP4028033A4 (en) * | 2019-09-12 | 2023-10-04 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| TW202227616A (zh) | 2020-08-21 | 2022-07-16 | 美商英麥提克斯股份有限公司 | 分離ｃｄ８＋選擇ｔ細胞的方法 |
| DE102021100038A1 (de) | 2020-12-31 | 2022-06-30 | Immatics US, Inc. | Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung |
| MX2023007817A (es) | 2020-12-31 | 2023-09-13 | Immatics Us Inc | Polipéptidos de cd8, composiciones y métodos de uso de estos. |
| KR20240004937A (ko) | 2021-05-05 | 2024-01-11 | 이매틱스 바이오테크놀로지스 게엠베하 | Bma031 항원 결합 폴리펩타이드 |
| US20230089392A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
| WO2023081461A1 (en) | 2021-11-08 | 2023-05-11 | Immatics US, Inc. | Methods for generating cell spheroids |
| CA3250304A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | IL-15 Bound to a Membrane, CD8 Polypeptides, Cells, Compositions and Related Methods of Use |
| WO2023212655A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| JP2025515604A (ja) | 2022-04-28 | 2025-05-20 | イマティクス ユーエス，アイエヌシー． | ドミナントネガティブＴＧＦβ受容体ポリペプチド、ＣＤ８ポリペプチド、細胞、組成物、およびその使用方法 |
| EP4519418A1 (en) | 2022-05-05 | 2025-03-12 | Immatics US, Inc. | Methods for improving t cell efficacy |
| WO2025096649A1 (en) | 2023-11-01 | 2025-05-08 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101287831B (zh) | 2005-09-13 | 2013-05-15 | 国立大学法人三重大学 | T细胞受体和编码该受体的核酸 |
| PT2172211E (pt) | 2008-10-01 | 2015-03-09 | Immatics Biotechnologies Gmbh | Composição de peptídeos associados a tumores e vacina anti -cancro relacionada para o tratamento de glioblastoma (gbm) e outros tipos de câncer |
| AU2014271235B2 (en) * | 2008-10-01 | 2017-03-02 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors including neuronal and brain tumors |
| TW201124530A (en) * | 2009-12-01 | 2011-07-16 | Oncotherapy Science Inc | IMP-3 oligopeptides and vaccines including the same |
| ES2925307T3 (es) * | 2012-09-14 | 2022-10-14 | Us Health | Receptores de linfocitos T que reconocen MAGE-A3 restringida al MHC de clase II |
| GB201319446D0 (en) * | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
-
2016
- 2016-03-16 GB GBGB1604494.3A patent/GB201604494D0/en not_active Ceased
-
2017
- 2017-03-16 PE PE2018001777A patent/PE20190124A1/es unknown
- 2017-03-16 UA UAA201809121A patent/UA124532C2/uk unknown
- 2017-03-16 MX MX2018011223A patent/MX2018011223A/es unknown
- 2017-03-16 MA MA45309A patent/MA45309B1/fr unknown
- 2017-03-16 EA EA201891759A patent/EA201891759A1/ru unknown
- 2017-03-16 CN CN201780017419.XA patent/CN108884143A/zh active Pending
- 2017-03-16 AU AU2017235069A patent/AU2017235069B2/en not_active Ceased
- 2017-03-16 CR CR20180490A patent/CR20180490A/es unknown
- 2017-03-16 BR BR112018067989-5A patent/BR112018067989A2/pt not_active IP Right Cessation
- 2017-03-16 SG SG11201807590SA patent/SG11201807590SA/en unknown
- 2017-03-16 US US15/461,020 patent/US10537624B2/en active Active
- 2017-03-16 EP EP17710963.4A patent/EP3430037B1/en active Active
- 2017-03-16 CA CA3017419A patent/CA3017419A1/en not_active Abandoned
- 2017-03-16 WO PCT/EP2017/056289 patent/WO2017158116A1/en not_active Ceased
- 2017-03-16 JP JP2018548050A patent/JP6929867B2/ja not_active Expired - Fee Related
- 2017-03-16 MA MA43328A patent/MA43328B2/fr unknown
- 2017-03-16 TW TW106108697A patent/TWI788284B/zh not_active IP Right Cessation
- 2017-03-16 KR KR1020187029658A patent/KR102266721B1/ko not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP6929867B2 (ja) | 2021-09-01 |
| AU2017235069B2 (en) | 2020-05-07 |
| CR20180490A (es) | 2019-01-10 |
| MX2018011223A (es) | 2018-11-22 |
| EA201891759A1 (ru) | 2019-02-28 |
| AU2017235069A1 (en) | 2018-10-04 |
| MA43328A1 (fr) | 2019-05-31 |
| WO2017158116A1 (en) | 2017-09-21 |
| SG11201807590SA (en) | 2018-10-30 |
| JP2019512242A (ja) | 2019-05-16 |
| KR102266721B1 (ko) | 2021-06-17 |
| EP3430037A1 (en) | 2019-01-23 |
| EP3430037B1 (en) | 2022-08-31 |
| TW201742873A (zh) | 2017-12-16 |
| GB201604494D0 (en) | 2016-04-27 |
| US10537624B2 (en) | 2020-01-21 |
| BR112018067989A2 (pt) | 2019-02-05 |
| MA45309A (fr) | 2019-01-23 |
| CN108884143A (zh) | 2018-11-23 |
| KR20180122430A (ko) | 2018-11-12 |
| UA124532C2 (uk) | 2021-10-05 |
| MA43328B2 (fr) | 2022-02-28 |
| US20170312350A1 (en) | 2017-11-02 |
| TWI788284B (zh) | 2023-01-01 |
| CA3017419A1 (en) | 2017-09-21 |
| MA45309B1 (fr) | 2023-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20190124A1 (es) | Linfocitos t transfectados y receptores de linfocito t para el uso en la inmunoterapia contra el cancer | |
| CO2018010808A2 (es) | Linfocitos t transfectados y receptores de linfocito t para el uso en la inmunoterapia contra el cáncer | |
| MX2018011225A (es) | Celulas t transfectadas y receptores de celulas t de utilidad en inmunoterapias contra el cancer. | |
| PH12018501933A1 (en) | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers | |
| CO2019008008A2 (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer | |
| CR20180074A (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de próstata y otros tipos de cáncer | |
| PE20240645A1 (es) | Peptido inmunogenico derivado de moleculas de antigenos leucocitarios humanos (hla) como biomarcador en la inmunoterapia de diversos tumores | |
| CO2019002466A2 (es) | Nuevos péptidos y estructuras de soporte para el uso en la inmunoterapia contra el carcinoma epidermoide de cabeza y cuello y otros tipos de cáncer | |
| MX2018011220A (es) | Peptidos y combinacion de peptidos para el uso en la inmunoterapia contra el cancer. | |
| CO2021004270A2 (es) | Péptidos restringidos por b*44 para el uso en la inmunoterapia contra el cáncer y métodos relacionados | |
| CL2020002953A1 (es) | Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra la leucemia y otros tipos de cáncer (divisional de la solicitud 201902878) | |
| CR20210141A (es) | Inmunoterapia con péptidos restringidos a a*01 y una combinación de péptidos contra el cáncer y métodos relacionados | |
| CL2020003371A1 (es) | Péptidos restringidos por a*03 para el uso en la inmunoterapia contra el cáncer y métodos relacionados | |
| CO2020013652A2 (es) | Péptidos para el uso en la inmunoterapia contra el cáncer | |
| CL2020001563A1 (es) | Péptidos (seq id no. 64, seq id no. 2 a seq id no. 63, seq id no. 65 a seq id no. 118, y seq id no. 120 a seq id no. 149), combinaciones de péptidos y células para el uso en la inmunoterapia contra el cáncer de vejiga urinaria y otros tipos de cáncer. (divisional solicitud 201802360) | |
| CL2020002857A1 (es) | Nuevos péptidos (seq id no: 146) y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el linfoma no hodgkiniano (lnh) y otros tipos de cáncer (divisional de la solicitud no. 201802096) | |
| CL2020002171A1 (es) | Nuevo péptido de seq id no: 12 y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra la leucemia mieloide aguda (lma) y otros tipos de cáncer. (divisional solicitud 201802827) | |
| AR107897A1 (es) | Linfocitos t transfectados y receptores de linfocito t para el uso en la inmunoterapia contra el cáncer | |
| AR114736A1 (es) | Péptidos restringidos por b*44 para el uso en la inmunoterapia contra el cáncer y métodos relacionados | |
| AR107898A1 (es) | Células t transfectadas y receptores de células t de utilidad en inmunoterapias contra el cáncer |